CIM
CLDX icon

CIM Investment Management’s Celldex Therapeutics CLDX Stock Holding History

CIM Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,678
Closed -$91K – 360
2017
Q1 		$91K Hold
1,678
– – 0.03% 352
2016
Q4 		$89K Hold
1,678
– – 0.03% 343
2016
Q3 		$102K Buy
1,678
+64
+4% +$3.99K 0.04% 342
2016
Q2 		$106K Buy
1,614
+164
+11% +$10.4K 0.04% 286
2016
Q1 		$82K Buy
1,450
+182
+14% +$20.5K 0.04% 268
2015
Q4 		$298K Hold
1,268
– – 0.14% 177
2015
Q3 		$200K Buy
+1,268
New +$359K 0.1% 235

Other funds holding CLDX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

CIM Investment Management's CLDX Position: Q2 2017 in Review

CIM Investment Management sold out of Celldex Therapeutics (CLDX) in Q2 2017, closing a stake of 1,678 shares — an estimated $91K sold.

CIM Investment Management first reported a position in CLDX in Q3 2015 and held it in 7 quarters. The position peaked at $298K in Q4 2015. 130 funds tracked by Wall St. Rank hold CLDX as of Q2 2017.

  • CIM Investment Management reported no remaining Celldex Therapeutics position as of Q2 2017 after selling out during the quarter.
  • CIM Investment Management sold 1,678 Celldex Therapeutics shares in Q2 2017, an estimated $91K.
  • CIM Investment Management first reported a position in Celldex Therapeutics in Q3 2015 and held it in 7 quarters.
  • CIM Investment Management's Celldex Therapeutics position peaked at $298K in Q4 2015.
  • 130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2017.

Based on CIM Investment Management's 13F filing for Q2 2017, filed 8 Aug 2017.